Rigel Pharmaceuticals, Inc.
393 articles with Rigel Pharmaceuticals, Inc.
-
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update
5/3/2022
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2022, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
4/26/2022
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2022 financial results after market close on Tuesday, May 3, 2022.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 08, 2022
4/8/2022
Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 626,000 shares of common stock to 15 newly hired employees.
-
Rigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
3/8/2022
Rigel Pharmaceuticals, Inc. announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibody autoimmune hemolytic anemia who had failed at least one prior treatment.
-
Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
3/1/2022
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
2/22/2022
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022.
-
Rigel Pharmaceuticals Provides Business Update - Jan 10, 2022
1/10/2022
Rigel Pharmaceuticals, Inc. provided a business update including preliminary 2021 full-year total revenue, the status of the Phase 3 study in COVID-19, and upcoming catalysts in 2022.
-
Rigel to Present at the J.P. Morgan Healthcare Conference
1/10/2022
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. ET on Wednesday, January 12, 2022.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Jan 08, 2022
1/8/2022
Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 610,000 shares of common stock to 14 newly hired employees.
-
When 2022 rolls around in a little more than a week, some Genentech employees will begin the new year in search of a new job.
-
Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
12/21/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ("Kissei"), has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP).
-
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
-
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
11/15/2021
Rigel Pharmaceuticals, Inc. announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts.
-
Rigel to Participate in Two Upcoming Investor Conferences
11/9/2021
Rigel Pharmaceuticals, Inc. today announced that Dean Schorno , the company's chief financial officer, will participate in the following virtual investor conferences in November: Jefferies Virtual London Healthcare Conference ( November 18-19, 2021 )
-
Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update
11/2/2021
Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2021, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update
10/26/2021
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2 , 2021.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Oct 08, 2021
10/8/2021
Rigel Pharmaceuticals, Inc. reported the grant of stock options to purchase an aggregate of 469,000 shares of common stock to 23 newly hired employees.
-
There were a fair number of clinical trial announcements last week. Here’s a look.
-
Rigel to Participate in Three Upcoming Investor Conferences in September 2021
9/2/2021
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in September.
-
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
9/1/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19